Table 4.

Treatments and Outcome for Patients With MDS/CMML and AML

Treatment Administered/Outcome	XRT (n = 47)		C/CMT (n = 181)		P (XRT v C/CMT)	De Novo (n = 222)		P (XRT v De Novo)
	No.	%	No.	%		No.	%
Highest intensity treatment					.4			.07
Supportive care	15	32	38	21		70	32
Low-intensity therapies	14	30	57	31		34	15
Induction chemotherapy	9	19	31	17		52	23
Bone marrow transplant	8	17	50	28		65	29
Unknown	1	2	5	3		1	0.5
Median survival (all patients)	n = 47		n = 181			n = 222
OS, months	22		11		.006	22		.8
95% CI	15 to 52		9 to 13			17 to 29
Median survival of patients with MDS/CMML	n = 26		n = 118			n = 103
OS, months	38		12		< .001	30		.9
95% CI	19 to 63		8 to 13			21 to 39
PFS to AML or death, months	33.0		9.4		.002	22.8		.8
95% CI	9 to 57		6 to 12			12 to 30
Median survival of patients with AML*	n = 29		n = 89			n = 148
OS, months	16		11		.03	18		.8
95% CI	10 to 38		8 to 14			12 to 24
Median survival of patients age ≤ 75 with AML*	n = 20		n = 82			n = 124
OS, months	38		12		.003	20		.2
95% CI	15 to 98		8 to 15			16 to 28

Abbreviations: AML, acute myeloid leukemia; C/CMT, cytotoxic chemotherapy/combined-modality therapy; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; OS, overall survival; PFS, progression-free survival; XRT, external-beam radiation therapy.

^*From time of AML diagnosis, including patients with MDS/CMML who transformed to AML (eight patients in XRT group, 28 patients in C/CMT group, and 28 patients in de novo group).